DE60325614D1 - 5-ÄÄ(2,3-Difluorophenyl)methylÜthioÜ-7-ÄÄ2-hydroxy-1-(hydroxymethyl)-1-methylethylÜaminoÜthiazoloÄ4,5-dÜpyrimidin-2(3H)-on Natrium Salz als CXCR2 Antagonist - Google Patents

5-ÄÄ(2,3-Difluorophenyl)methylÜthioÜ-7-ÄÄ2-hydroxy-1-(hydroxymethyl)-1-methylethylÜaminoÜthiazoloÄ4,5-dÜpyrimidin-2(3H)-on Natrium Salz als CXCR2 Antagonist

Info

Publication number
DE60325614D1
DE60325614D1 DE60325614T DE60325614T DE60325614D1 DE 60325614 D1 DE60325614 D1 DE 60325614D1 DE 60325614 T DE60325614 T DE 60325614T DE 60325614 T DE60325614 T DE 60325614T DE 60325614 D1 DE60325614 D1 DE 60325614D1
Authority
DE
Germany
Prior art keywords
diphyrimidin
difluorophenyl
methylethyl
methylthio
hydroxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325614T
Other languages
English (en)
Inventor
Roger Victor Bonnert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60325614D1 publication Critical patent/DE60325614D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60325614T 2002-09-20 2003-09-16 5-ÄÄ(2,3-Difluorophenyl)methylÜthioÜ-7-ÄÄ2-hydroxy-1-(hydroxymethyl)-1-methylethylÜaminoÜthiazoloÄ4,5-dÜpyrimidin-2(3H)-on Natrium Salz als CXCR2 Antagonist Expired - Lifetime DE60325614D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221828.7A GB0221828D0 (en) 2002-09-20 2002-09-20 Novel compound
PCT/GB2003/003998 WO2004026880A1 (en) 2002-09-20 2003-09-16 Novel compound

Publications (1)

Publication Number Publication Date
DE60325614D1 true DE60325614D1 (de) 2009-02-12

Family

ID=9944428

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325614T Expired - Lifetime DE60325614D1 (de) 2002-09-20 2003-09-16 5-ÄÄ(2,3-Difluorophenyl)methylÜthioÜ-7-ÄÄ2-hydroxy-1-(hydroxymethyl)-1-methylethylÜaminoÜthiazoloÄ4,5-dÜpyrimidin-2(3H)-on Natrium Salz als CXCR2 Antagonist

Country Status (27)

Country Link
US (2) US7585867B2 (de)
EP (1) EP1543013B1 (de)
JP (1) JP4619787B2 (de)
KR (1) KR20050057427A (de)
CN (1) CN1315848C (de)
AR (1) AR041340A1 (de)
AT (1) ATE419254T1 (de)
AU (1) AU2003267571B2 (de)
BR (1) BR0314844A (de)
CA (1) CA2498762A1 (de)
DE (1) DE60325614D1 (de)
DK (1) DK1543013T3 (de)
ES (1) ES2318152T3 (de)
GB (1) GB0221828D0 (de)
HK (1) HK1077060A1 (de)
IS (1) IS7793A (de)
MX (1) MXPA05002935A (de)
NO (1) NO20051892L (de)
NZ (1) NZ538826A (de)
PL (1) PL375952A1 (de)
PT (1) PT1543013E (de)
RU (1) RU2342389C2 (de)
SI (1) SI1543013T1 (de)
TW (1) TW200413395A (de)
UA (1) UA81257C2 (de)
WO (1) WO2004026880A1 (de)
ZA (1) ZA200502272B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
WO2007019191A2 (en) * 2005-08-08 2007-02-15 Janssen Pharmaceutica, N.V. Thiazolopyrimidine kinase inhibitors
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
TW200942549A (en) 2007-12-17 2009-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
AR071036A1 (es) * 2008-03-26 2010-05-19 Astrazeneca Ab Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
EP2516416A1 (de) 2009-12-23 2012-10-31 Ironwood Pharmaceuticals, Inc. Crth2-modulatoren
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2924472A (en) 1957-06-27 1960-02-09 Gen Motors Corp Pipe joint seal
GB1009477A (en) 1962-02-13 1965-11-10 Smith Kline French Lab Novel process for preparing heterocyclic compounds
US3318900A (en) 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
BE668603A (de) 1964-08-20
DE2331223C2 (de) 1972-06-19 1984-11-22 Kohjin Co., Ltd., Tokio / Tokyo S-substituierte-2-Thioadenosine, deren 5'-Monophosphate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten
US4120521A (en) 1975-08-28 1978-10-17 Rieber & Son Plastic-Industri A/S Combined mould element and sealing ring
EG12406A (en) 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
GB1600293A (en) 1977-02-04 1981-10-14 British Oceanics Ltd Sealing arrangements
US4188040A (en) 1977-04-06 1980-02-12 Firma WOCO Franz-Josef Wolf & Co. Sealing ring
DE2726959A1 (de) 1977-06-15 1979-01-18 Arlt Christian Dichteinsatz zum dichten verbinden von zwei rohren
FR2421899A1 (fr) 1978-01-16 1979-11-02 Roussel Uclaf Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits
US4410528A (en) 1980-05-16 1983-10-18 Kyowa Hakko Kogyo Co., Ltd. Hypotensive piperidine derivatives
DE3219522A1 (de) 1981-10-28 1983-12-01 Denso-Chemie Wedekind Kg, 5090 Leverkusen Steckmuffendichtung fuer rohre
FR2547888B1 (fr) 1983-06-22 1985-12-13 Sabla Sa Bague d'etancheite a implants pour tuyaux a emboitement
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
SE8800348L (sv) 1988-02-03 1989-08-04 Forsheda Ab Taetningsring och verktyg foer framstaellning daerav
FR2659656B1 (fr) 1990-03-15 1994-09-09 Sanofi Sa Derives de pyrimidinedione-2,4 et medicaments les contenant.
DE4119767A1 (de) 1991-06-15 1992-12-17 Dresden Arzneimittel Verfahren zur herstellung von (pyrimid-2-yl-thio- bzw. seleno)-essigsaeurederivaten
US5169161A (en) 1991-09-19 1992-12-08 Hail Mary Rubber Co., Inc. Symmetrical gasket for pipe joints
DE4134089C2 (de) 1991-10-15 1994-10-13 Dueker Eisenwerk Schubgesicherte Muffenverbindung
JPH05188994A (ja) 1992-01-07 1993-07-30 Sony Corp 騒音抑圧装置
DE4229609C2 (de) 1992-09-04 2003-05-08 Forsheda Stefa Gmbh Abdichtung zwischen zwei ineinandersteckbaren Teilen
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
DE69628804T2 (de) 1995-12-08 2003-12-18 Pfizer Inc., New York Substitutierte heterozyclische Derivate als CRF Antagonisten
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SE515033C2 (sv) 1995-12-27 2001-06-05 Forsheda Ab Tätningsanordning
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
AU2388697A (en) 1996-04-19 1997-11-12 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
CN1227554A (zh) 1996-08-28 1999-09-01 辉瑞大药厂 取代的6,5－杂二环衍生物
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO1998025617A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JP2002510327A (ja) 1997-07-25 2002-04-02 メルク エンド カンパニー インコーポレーテッド 環状アミンケモカイン受容体活性調節剤
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
NZ504800A (en) 1997-11-28 2001-10-26 Sumitomo Pharma 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof
PT1049689E (pt) 1998-01-19 2002-09-30 Pfizer Compostos de 4-(2-ceto-1-benzimidazolinil)piperidina como agonistas do receptor orl1
AU747508B2 (en) 1998-03-19 2002-05-16 Nihon Nohyaku Co., Ltd. Arylpiperidine derivatives and use thereof
AU3213699A (en) 1998-04-03 1999-10-25 Du Pont Pharmaceuticals Company Thiazolo(4,5-d)pyrimidines and pyridines as corticotropin releasing factor (CRF)antagonists
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
US5988695A (en) 1998-08-26 1999-11-23 S&B Technical Products, Inc. Pipe gasket with embedded ring
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
AU770551B2 (en) 1998-12-28 2004-02-26 4-Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1187615A2 (de) 1999-02-02 2002-03-20 K.U. Leuven Research & Development Immunodepressive effekte von pteridin-derivaten
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6142484A (en) 1999-04-15 2000-11-07 Vassallo Research & Development Corporation Composite multi-pressure gasket
US6432981B1 (en) 1999-06-11 2002-08-13 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
MXPA02001108A (es) 1999-09-15 2002-08-20 Warner Lambert Co Pieridinonas como inhibidores de la cinasa.
PE20010628A1 (es) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
DE60023100T2 (de) 2000-01-05 2006-07-06 Pfizer Inc. Benzimidazol-Verbindungen zur Verwendung als ORL1-Rezeptor-Antagonisten
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
ATE255584T1 (de) 2000-02-11 2003-12-15 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
GB2359079A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
WO2001070689A1 (fr) 2000-03-24 2001-09-27 Meiji Seika Kaisha, Ltd. DERIVES DE LA DIPHENYLALKYLAMINE UTILES COMME AGONISTES DU RECEPTEUR DE L'OPIOIDE $g(d)
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
PL359181A1 (en) 2000-07-07 2004-08-23 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0004110L (sv) 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SE0102716D0 (sv) 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
KR20060120014A (ko) 2003-10-07 2006-11-24 아스트라제네카 아베 케모킨, 특히 ｃｘ3ｃｒ1 수용체 길항제로서 유용한 신규한2-치환된 4-아미노-티아졸로[4,5-ｄ]피리미딘
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2008524186A (ja) 2004-12-17 2008-07-10 アストラゼネカ・アクチエボラーグ ケモカイン受容体活性の調節のためのチアゾロピラミジン化合物

Also Published As

Publication number Publication date
GB0221828D0 (en) 2002-10-30
WO2004026880A1 (en) 2004-04-01
MXPA05002935A (es) 2005-05-27
JP4619787B2 (ja) 2011-01-26
CA2498762A1 (en) 2004-04-01
JP2006503835A (ja) 2006-02-02
NZ538826A (en) 2006-12-22
RU2342389C2 (ru) 2008-12-27
PT1543013E (pt) 2009-02-27
UA81257C2 (en) 2007-12-25
US20060100221A1 (en) 2006-05-11
SI1543013T1 (sl) 2009-04-30
DK1543013T3 (da) 2009-03-09
EP1543013B1 (de) 2008-12-31
HK1077060A1 (en) 2006-02-03
BR0314844A (pt) 2005-08-09
ZA200502272B (en) 2005-09-19
CN1681826A (zh) 2005-10-12
KR20050057427A (ko) 2005-06-16
AR041340A1 (es) 2005-05-11
AU2003267571A1 (en) 2004-04-08
ATE419254T1 (de) 2009-01-15
US20080306262A1 (en) 2008-12-11
NO20051892L (no) 2005-06-17
ES2318152T3 (es) 2009-05-01
RU2005106356A (ru) 2005-11-20
CN1315848C (zh) 2007-05-16
EP1543013A1 (de) 2005-06-22
IS7793A (is) 2005-04-11
PL375952A1 (en) 2005-12-12
TW200413395A (en) 2004-08-01
US7585867B2 (en) 2009-09-08
AU2003267571B2 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
DE60325614D1 (de) 5-ÄÄ(2,3-Difluorophenyl)methylÜthioÜ-7-ÄÄ2-hydroxy-1-(hydroxymethyl)-1-methylethylÜaminoÜthiazoloÄ4,5-dÜpyrimidin-2(3H)-on Natrium Salz als CXCR2 Antagonist
DE60315354D1 (de) Pyridazinon-derivate als gsk-3beta-hemmer
ATE387445T1 (de) Pyridino 2,3-d pyrimidin-derivate als selektive kdr- und fgfr-inhibitoren
LU92595I2 (fr) Siméprévir, ou l&#39;un de ses sels pharmaceutiquementacceptables, incluant siméprévir sodium
NO20022573L (no) N6-heterosykliske, 8-modifiserte adenosinderivater
DE50302202D1 (de) Neue 2,5-disubstituierte pyrimidinderivate
DE60325613D1 (de) 5-Ä((2,3-difluorophenyl)methyl)thioÜ-7-äÄ(1S,2S)-2-hydroxy-1-(hydroxymethyl)propylÜaminoüthiazoloÄ4,5-dÜpyrimidin-2(3H)-on als CXCR2 Antagonist
DE50208895D1 (de) Substituierte 2-thio-3, 5-dicyano-4-aryl-6-aminopyridine und ihre verwendung als adenosinrezeptor-selektive liganden
ATE229955T1 (de) Substituierte 1,8-naphthyridin-4(1h)-one als phosphodiesterase 4-inhibitoren
DE60120419D1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
NO20016128L (no) Substituerte, heterocykliske, fuserte &lt;gamma&gt;-karboliner
ATE354570T1 (de) 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
DE60037345D1 (de) Pyrroloi2,3-d pyrimidinderivate enthaltende Zusammensetzungen
PT1381363E (pt) Derivados de imidazo-(1,2-a)-piridina como antagonistas mglur5
DE60201437D1 (de) 2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten
ATE278690T1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
DE60203481D1 (de) Piperidinderivate als neurokinin 1 antagonisten
PT1355639E (pt) Derivados de carboestirilo substituidos como agonistas do subtipo de receptores 5-ht1a
ATE306265T1 (de) Benzothiazolderivate als adenosin-rezeptor- liganden
DE60133931D1 (de) Kondensierte purinderivate als a1-adenosinrezeptorantagonisten
NL1024677A1 (nl) Therapeutische prolinederivaten.
ATE325117T1 (de) 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten
PT1387923E (pt) Coroa de perfuracao.
DE60214408D1 (de) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN

Legal Events

Date Code Title Description
8364 No opposition during term of opposition